Richard L. Love

Mr. Love’s career spans 38 years with more than 24 years of leadership roles in the oncology-focused biosciences. He is presently the Managing Director of the TRAC Venture Fund and Ascalon Pharma. He started multiple biopharmaceutical companies, including Triton Biosciences Inc. and ILEX Oncology Inc. (ILXO), and served as CEO of both companies for periods of eight years each. In addition, Mr.Love has served in executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center (CTRC), The San Antonio Technology Accelerator Initiative (SATAI), and the Translational Genomics Research Institute (TGen). Mr.Love joined TGen in January 2003 as its Chief Operating Officer. At Triton and ILXO, Mr. Love led teams that were responsible for the clinical development of multiple important therapeutic products, four of which are currently in the practice of medicine: Betaseron for patients with multiple sclerosis; Fludara and CAMPATH both for patients with chronic lymphocytic leukemia; and Clolar for acute lymphocytic leukemia. In 2004 ILXO was acquired by Genzyme Corporation in stock for a stock transaction valued at approximately $1.0 billion. Mr. Love also serves on the Board of Directors of Parexel International.